The company is developing two manufacturing and development facilities that will add just over 22,000 sf to its complex.
The firm said this week it has all but finished its 10,300-sf manufacturing center. The building incorporates robotics technology and is designed for the production of gene therapy products. Avigen plans to finish its second building, a 12,000-sf process development facility, in November.
The company reported increased losses of $15 million in Q2 due to less grant funding, but has raised $75 million in private funding during fiscal 2000.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
